Divi's Laboratories Reports Q1 Results with Consolidated Total Income of 3,144 Crores; Key Management Appointments Made
Divi's Laboratories Limited announced its financial results for the quarter ended June 30, 2026, revealing a consolidated total income of 3,144 crores. The company also approved several appointments to its senior management team.The Board meeting held on August 01, 2026, focused on reviewing the unaudited financial results and approving significant personnel changes.
Consolidated Financial Performance Highlights
For the quarter ended June 30, 2026, the company reported a consolidated total income of 3,144 crores, compared to 2,529 crores in the corresponding quarter of the previous financial year. Profit before tax (PBT) stood at 1,180 crores, up from 733 crores previously. The profit after tax (PAT) for the current quarter was 902 crores, marking an increase from 545 crores in the prior period.The company recorded a forex loss of 7 crores in the current quarter, down from a forex gain of 39 crores in the previous year's corresponding quarter.
A summary of the consolidated unaudited financial results for the quarter ended June 30, 2026 is presented below:
| Particular | Qtr Ended 30.06.2026 (Unaudited) | Qtr Ended 31.03.2026 (Audited) | Qtr Ended 30.06.2025 (Unaudited) | Year Ended 31.03.2026 (Audited) |
|---|---|---|---|---|
| Revenue from operations | 3,080 | 2,831 | 2,410 | 10,560 |
| Total Income | 3,144 | 2,986 | 2,529 | 11,067 |
| Total Expenses | 1,964 | 2,023 | 1,796 | 7,605 |
| Profit before tax | 1,180 | 963 | 733 | 3,462 |
| Tax expense | 278 | 212 | 188 | 820 |
| Profit for the period (PAT) | 902 | 751 | 545 | 2,568 |
Standalone Earnings and Forex Status
On a standalone basis, Divi's Laboratories Limited reported total income of 3,037 crores for the quarter ended June 30, 2026. Profit before tax (PBT) was recorded at 1,165 crores, while profit after tax (PAT) stood at 891 crores, compared to 557 crores in the previous financial year.Regarding foreign exchange fluctuations, the standalone entity reported a forex loss of 7 crores for the current quarter, contrasting with a forex gain of 39 crores recorded against the prior period's corresponding quarter.
| Particular | Qtr Ended 30.06.2026 | Qtr Ended 30.06.2025 |
|---|---|---|
| Forex Gain/(Loss) | (7) crores | 39 crores |
Senior Management Appointments
The Board meeting also approved the appointment of two key personnel as Senior Management, effective August 01, 2026. These appointments were made as recommended by the Nomination and Remuneration Committee.Mr. B. Vara Prasad was appointed General Manager (Engineering Purchase), while Mr. J. Srinivasa Rao was appointed General Manager (Raw Materials Purchase).
Details of the appointees are available in the annexed schedule:
| S.No | Name | Role/Appointment | Date of Appointment | Brief Profile Summary |
|---|---|---|---|---|
| 1 | Mr. B. Vara Prasad | General Manager (Engineering Purchase) | August 01, 2026 | Holds an MBA and has over 31 years of experience in the pharmaceutical industry. He is responsible for engineering related procurement and strategic sourcing within the company. |
| 2 | Mr. J. Srinivasa Rao | General Manager (Raw Materials Purchase) | August 01, 2026 | Holds an MBA and possesses over 30 years of experience in managing procurement operations. He is responsible for end-to-end raw materials procurement at the company. |
DIVISLAB Stock Price Movement
On Friday, shares of Divi's Laboratories Limited rallied strongly, closing at ₹8056 after edging higher to register a 3.19% gain. The stock recorded robust trading activity with 793,919 shares transacted, pushing the equity near its annual high established earlier this year at ₹8090.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.